Unknown

Dataset Information

The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir.


ABSTRACT: Traditional cancer treatments may lose efficacy following the emergence of novel mutations or the development of chemoradiotherapy resistance. Late diagnosis, high-cost of treatment, and the requirement of highly efficient infrastructure to dispense cancer therapies hinder the availability of adequate treatment in low-income and resource-limited settings. Repositioning approved drugs as cancer therapeutics may reduce the cost and timeline for novel drug development and expedite the availability of newer, efficacious options for patients in need. Nelfinavir is a human immunodeficiency virus (HIV) protease inhibitor that has been approved and is extensively used as an anti-infective agent to treat acquired immunodeficiency syndrome (AIDS). Yet nelfinavir has also shown anti-cancer effects in

SUBMITTER: Subeha MR 

PROVIDER: S-EPMC7699465 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature